2022 World Conference on Lung Cancer (ePosters)-EP16.01-015. Introducing "BiomeOne" a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients

EP16.01-015. Introducing "BiomeOne" a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients

Back to course

Pdf Summary

A study was conducted to evaluate the prognostic potential of BiomeOne, a tumor-agnostic medical device that uses baseline stool samples to analyze the intestinal microbiome and predict patient response to immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) patients. The study found that BiomeOne had an overall sensitivity of 81% and a specificity of 55% in the NSCLC cohort. Out of the 31 patients classified as responders after ICI treatment, BiomeOne correctly identified 25 patients based on the microbial profile of their baseline stool samples. <br /><br />The research team used the ALDEx2 algorithm to identify differentially abundant bacteria between responders and non-responders. The results showed that certain bacteria, including g_Sutterella and g_[Eubacterium] eligens group, were significantly different in abundance between the two groups. Additionally, no significant differences were found in alpha-diversity between responders and non-responders.<br /><br />The study suggests that BiomeOne can serve as a clinical support tool for oncologists in therapy decision-making, allowing for more targeted application of ICI therapies and potentially improving patient well-being and recovery. The large number of included datasets in the research led to a robust biomarker that takes into account multiple confounding factors, such as sample preparation and analysis methods.<br /><br />These findings indicate that BiomeOne has the potential to be a valuable tool in predicting patient response to ICI therapy in NSCLC. Further research and validation studies are warranted to confirm these results and optimize the use of BiomeOne in clinical practice.

Asset Subtitle

Maximilian Johannes Hochmair

Meta Tag

Speaker Maximilian Johannes Hochmair

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

BiomeOne

tumor-agnostic medical device

intestinal microbiome

patient response

immune checkpoint inhibitor therapy

non-small cell lung cancer

sensitivity

specificity

differentially abundant bacteria

clinical support tool